Please Download Flash

Browse News by Year:
  RSS
News Highlights:

Liazon Closes $18.2M in Funding to Expand Private Benefits Exchange

April 24, 2012 - Liazon, which operates the market-leading Bright Choices(R) private health benefits exchange, has closed $18.2 million in new funding from investors to expand nationwide and develop new products. Bessemer Venture Partners and Fidelity Biosciences led the round with follow-on funding from existing investors Bain Capital Ventures and Rand Capital, SBIC. View Full Article

Mersana Therapeutics Enters Collaboration with Endo Pharmaceuticals to Develop Next-generation Antibody-drug Conjugates

March 7, 2012 - Mersana Therapeutics, Inc. announced today that it has entered into a collaboration agreement with Endo Pharmaceuticals (Nasdaq: ENDP) to develop next-generation antibody-drug conjugates (ADCs). Mersana’s proprietary conjugation technology is comprised of the Company’s Fleximer® polymer and a broad array of customizable linker chemistries for attaching diverse, potent payloads and targeted antibodies. Under this agreement, Endo will pay an upfront fee to Mersana for the right to utilize the Fleximer technology to develop novel ADC candidates against a single cancer target.
View Full Article

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

February 16, 2012 - Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product candidate in Tetraphase's clinical pipeline. Tetraphase will be working on this contract with Buffalo, NY-based CUBRC, Inc. View Full Article

Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice

February 7, 2012 - Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice® (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Effective and well-tolerated, Sklice Lotion treats lice in most patients with a single 10-minute application of the lotion, without nit combing. View Full Article

Ultragenyx In-Licenses Therapeutic Program for Rare Genetic Disease Mucopolysaccharidosis Type 7 from St. Louis University

January 5, 2012 - Ultragenyx Pharmaceutical, Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has in-licensed an enzyme replacement therapy program from St. Louis University to treat mucopolysaccharidosis type 7 (MPS 7). The in-licensed program is a treatment for an ultra-rare genetic, metabolic disorder that results from the deficiency of the beta-glucuronidase (GUS) enzyme. Also known as Sly syndrome, the disorder was first identified in 1973 by William S. Sly, MD, a world-renowned researcher in inherited diseases, who is currently Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, at St. Louis University School of Medicine. Dr. Sly will collaborate with Ultragenyx on the MPS 7 development program. View Full Article

Cornerstone Therapeutics Acquires Cardiokine

January 4, 2012 - Cornerstone Therapeutics (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products for the hospital and respiratory markets, today announced that it has acquired Cardiokine Inc., a specialty pharmaceutical company focused on developing hospital products for cardiovascular indications. The merger was effective Dec. 30, 2011. View Full Article